Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C–IV non-squamous NSCLC. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2024
10.3322/caac.21820 · 2024 · External reference
New promises and challenges in the treatment of advanced non-small-cell lung cancer
10.1016/s0140-6736(24)01029-8 · 2024 · External reference
Immunotherapy in non-small cell lung cancer: Update and new insights
10.18053/jctres.07.202101.001 · 2021 · External reference
First-line tislelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: PD-L1 ≥ 50% subgroup analysis from the RATIONALE-304 trial
10.1007/s40487-025-00378-8 · 2025 · External reference
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: Final analysis of the randomized, phase III RATIONALE-307 trial
10.1016/j.esmoop.2024.103727 · 2024 · External reference
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
10.1016/j.jhepr.2022.100498 · 2022 · External reference
Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
10.1200/jco.21.01308 · 2022 · External reference
Global cancer burden: Progress, projections, and challenges
10.1016/s0140-6736(25)01570-3 · 2025 · External reference
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: Promising strategies to overcoming challenges
10.3389/fimmu.2024.1366260 · 2024 · External reference
Survival improvement of stage IV non-small cell lung cancer in the immunotherapy era: A retrospective cohort study in a US population
10.1007/s12325-024-03027-0 · 2024 · External reference
Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer
10.1200/jco.19.03136 · 2020 · External reference
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(19)30167-6 · 2019 · External reference
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC
10.1016/j.jtho.2021.07.009 · 2021 · External reference
Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
10.1200/jco.22.01989 · 2023 · External reference
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial
10.1016/s2213-2600(20)30365-9 · 2020 · External reference
Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial
10.1016/j.jtho.2021.05.005 · 2021 · External reference
Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study
10.1016/j.jtho.2021.07.015 · 2021 · External reference
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): Interim and final analyses of a double-blind, randomised, phase 3 clinical trial
10.1016/s1470-2045(21)00650-1 · 2022 · External reference
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
10.1172/jci138740 · 2021 · External reference
Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer with high tumor mutation burden: A nonrandomized controlled trial
10.1001/jamaoncol.2022.5959 · 2022 · External reference
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: Final, 6-year outcomes from CheckMate 9LA
10.1016/j.esmoop.2025.105123 · 2025 · External reference
Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: Retrospective analysis of two single-institution prospective trials
10.1136/jitc-2019-000492 · 2020 · External reference
A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer
10.1016/j.cllc.2021.01.012 · 2021 · External reference
Nivolumab and stereotactic radiation therapy for the treatment of patients with stage IV non-small-cell lung cancer
10.1093/jjco/hyy171 · 2018 · External reference
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: An FDA pooled analysis
10.1016/s1470-2045(24)00040-8 · 2024 · External reference
